Clinical Trial Update: 9-valent CRM 197 Pneumococcal [Phase 2]

View source ↗

Summary

A Phase 2 trial of a 9-valent CRM197-conjugated pneumococcal vaccine has completed; the update provides no detailed efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• 9-valent CRM197 pneumococcal vaccine (CRM197-conjugated pneumococcal vaccine (9-valent))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Pneumococcal Infection | Phase 2 | Status: COMPLETED